Ligand-targeted theranostic nanomedicines against cancer

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 267-286

  Yao, Virginia J ^a,b   D'Angelo, Sara ^a,b   Butler, Kimberly S ^c   Theron, Christophe ^c   Smith, Tracey L ^a,b   Marchiò, Serena ^a,b,d   Gelovani, Juri G ^e   Sidman, Richard L ^f   Dobroff, Andrey S ^a,b   Brinker, C Jeffrey ^a,c,g,h   Bradbury, Andrew R M ⁱ   Arap, Wadih ^a,b   Pasqualini, Renata ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c University of New Mexico   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e Wayne State University   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h SANDIA NATIONAL LABORATORIES   (United States)

ⁱ LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Antibody display; Peptide ligands; Phage display; Protocells; Tumor targeting

Indexed keywords

ANTIBODIES; BIOCOMPATIBILITY; CELL MEMBRANES; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; ENDOTHELIAL CELLS; ENZYME INHIBITION; GENE THERAPY; LIGANDS; LIPID BILAYERS; PEPTIDES; SILICA; TUMORS;

CELL SURFACE RECEPTORS; COMBINATORIAL PEPTIDE LIBRARIES; PEPTIDE LIGAND; PHAGE DISPLAY; PHAGE DISPLAY TECHNOLOGY; PROTOCELLS; SINGLE CHAIN VARIABLE FRAGMENTS; TUMOR TARGETING;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; APTAMER; AVIDIN; BINDING PROTEIN; NANOCARRIER; NEUTRAVIDIN; PEPTIDE; POLYHISTIDINE TAG; RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STREPTAVIDIN; TUMOR RECEPTOR; UNCLASSIFIED DRUG; DRUG; DRUG CARRIER; NANOMATERIAL;

ARTICLE; CLICK CHEMISTRY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; NANOPHARMACEUTICS; NEOPLASM; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; THERANOSTIC NANOMEDICINE; BLOOD; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR TARGETED THERAPY; NANOSTRUCTURES; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; THERANOSTIC NANOMEDICINE;

EID: 84955607181     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.01.002     Document Type: Article

References (357)

1. [1] Choi, H.S., Liu, W., Misra, P., Tanaka, E., Zimmer, J.P., Itty Ipe, B., Bawendi, M.G., Frangioni, J.V., Renal clearance of quantum dots. Nat. Biotechnol. 25 (2007), 1165–1170.
2. [2] Nguyen, T., Tekrony, A., Yaehne, K., Cramb, D.T., Designing a better theranostic nanocarrier for cancer applications. Nanomedicine (London) 9 (2014), 2371–2386.
3. [3] Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R.K., McDonald, D.M., Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156 (2000), 1363–1380.
4. [4] Ozawa, M.G., Yao, V.J., Chanthery, Y.H., Troncoso, P., Uemura, A., Varner, A.S., Kasman, I.M., Pasqualini, R., Arap, W., McDonald, D.M., Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 104 (2005), 2104–2115.
5. [5] Pasqualini, R., Arap, W., McDonald, D.M., Probing the structural and molecular diversity of tumor vasculature. Trends Mol. Med. 8 (2002), 563–571.
6. [6] Fang, J., Nakamura, H., Maeda, H., The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63 (2011), 136–151.
7. [7] Iyer, A.K., Khaled, G., Fang, J., Maeda, H., Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11 (2006), 812–818.
8. [8] Mahon, E., Salvati, A., Baldelli Bombelli, F., Lynch, I., Dawson, K.A., Designing the nanoparticle–biomolecule interface for “targeting and therapeutic delivery”. J. Control. Release 161 (2012), 164–174.
9. [9] Arap, W., Pasqualini, R., Ruoslahti, E., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998), 377–380.
10. [10] Bradbury, A.R., Marks, J.D., Antibodies from phage antibody libraries. J. Immunol. Methods 290 (2004), 29–49.
11. [11] Curnis, F., Arrigoni, G., Sacchi, A., Fischetti, L., Arap, W., Pasqualini, R., Corti, A., Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62 (2002), 867–874.
12. [12] Dias-Neto, E., Nunes, D.N., Giordano, R.J., Sun, J., Botz, G.H., Yang, K., Setubal, J.C., Pasqualini, R., Arap, W., Next-generation phage display: integrating and comparing available molecular tools to enable cost-effective high-throughput analysis. PLoS One, 4, 2009, e8338.
13. [13] Ferrara, F., D'Angelo, S., Gaiotto, T., Naranjo, L., Tian, H., Graslund, S., Dobrovetsky, E., Hraber, P., Lund-Johansen, F., Saragozza, S., Sblattero, D., Kiss, C., Bradbury, A.R., Recombinant renewable polyclonal antibodies. mAbs 7 (2015), 32–41.
14. [14] Ferrara, F., Naranjo, L.A., Kumar, S., Gaiotto, T., Mukundan, H., Swanson, B., Bradbury, A.R., Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker. PLoS One, 7, 2012, e49535.
15. [15] Gregorc, V., De Braud, F.G., De Pas, T.M., Scalamogna, R., Citterio, G., Milani, A., Boselli, S., Catania, C., Donadoni, G., Rossoni, G., Ghio, D., Spitaleri, G., Ammannati, C., Colombi, S., Caligaris-Cappio, F., Lambiase, A., Bordignon, C., Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin. Cancer Res. 17 (2011), 1964–1972.
16. [16] Gregorc, V., Zucali, P.A., Santoro, A., Ceresoli, G.L., Citterio, G., Pas, T.M. De, Zilembo, N., Vincenzo, F. De, Simonelli, M., Rossoni, G., Spreafico, A., Grazia Viganò, M., Fontana, F., Braud, F.G. De, Bajetta, E., Caligaris-Cappio, F., Bruzzi, P., Lambiase, A., Bordignon, C., Phase II study of asparagine–glycine–arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28 (2010), 2604–2611.
17. [17] Hajitou, A., Trepel, M., Lilley, C.E., Soghomonyan, S., Alauddin, M.M., Marini, F.C. 3rd, Restel, B.H., Ozawa, M.G., Moya, C.A., Rangel, R., Sun, Y., Zaoui, K., Schmidt, M., von Kalle, C., Weitzman, M.D., Gelovani, J.G., Pasqualini, R., Arap, W., A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125 (2006), 385–398.
18. [18] Kolonin, M.G., Bover, L., Sun, J., Zurita, A.J., Do, K.A., Lahdenranta, J., Cardó-Vila, M., Giordano, R.J., Jaalouk, D.E., Ozawa, M.G., Moya, C.A., Souza, G.R., Staquicini, F.I., Kunyiasu, A., Scudiero, D.A., Holbeck, S.L., Sausville, E.A., Arap, W., Pasqualini, R., Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res. 66 (2006), 34–40.
19. [19] Kolonin, M.G., Saha, P.K., Chan, L., Pasqualini, R., Arap, W., Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 10 (2004), 625–632.
20. [20] Kolonin, M.G., Sun, J., Do, K.A., Vidal, C.I., Ji, Y., Baggerly, K.A., Pasqualini, R., Arap, W., Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J. 20 (2006), 979–981.
21. [21] Krag, D.N., Shukla, G.S., Shen, G.P., Pero, S., Ashikaga, T., Fuller, S., Weaver, D.L., Burdette-Radoux, S., Thomas, C., Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 66 (2006), 7724–7733.
22. [22] Paoloni, M.C., Tandle, A., Mazcko, C., Hanna, E., Kachala, S., Leblanc, A., Newman, S., Vail, D., Henry, C., Thamm, D., Sorenmo, K., Hajitou, A., Pasqualini, R., Arap, W., Khanna, C., Libutti, S.K., Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One, 4, 2009, e4972.
23. [23] Pasqualini, R., Millikan, R.E., Christianson, D.R., Cardó-Vila, M., Driessen, W.H., Giordano, R.J., Hajitou, A., Hoang, A.G., Wen, S., Barnhart, K.F., Baze, W.B., Marcott, V.D., Hawke, D.H., Do, K.A., Navone, N.M., Efstathiou, E., Troncoso, P., Lobb, R.R., Logothetis, C.J., Arap, W., Targeting the interleukin-11 receptor alpha in metastatic prostate cancer: a first-in-man study. Cancer 121 (2015), 2411–2421.
24. [24] Pasqualini, R., Ruoslahti, E., Organ targeting in vivo using phage display peptide libraries. Nature 380 (1996), 364–366.
25. [25] Sblattero, D., Bradbury, A., Exploiting recombination in single bacteria to make large phage antibody libraries. Nat. Biotechnol. 18 (2000), 75–80.
26. [26] Shukla, G.S., Krag, D.N., Peletskaya, E.N., Pero, S.C., Sun, Y.J., Carman, C.L., McCahill, L.E., Roland, T.A., Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies. Cancer Immunol. Immunother. 62 (2013), 1397–1410.
27. [27] Staquicini, F.I., Cardó-Vila, M., Kolonin, M.G., Trepel, M., Edwards, J.K., Nunes, D.N., Sergeeva, A., Efstathiou, E., Sun, J., Almeida, N.F., Tu, S.M., Botz, G.H., Wallace, M.J., O'Connell, D.J., Krajewski, S., Gershenwald, J.E., Molldrem, J.J., Flamm, A.L., Koivunen, E., Pentz, R.D., Dias-Neto, E., Setubal, J.C., Cahill, D.J., Troncoso, P., Do, K.A., Logothetis, C.J., Sidman, R.L., Pasqualini, R., Arap, W., Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 18637–18642.
28. [28] Staquicini, F.I., Ozawa, M.G., Moya, C.A., Driessen, W.H., Barbu, E.M., Nishimori, H., Soghomonyan, S., Flores, L.G. II, Liang, X., Paolillo, V., Alauddin, M.M., Basilion, J.P., Furnari, F.B., Bogler, O., Lang, F.F., Aldape, K.D., Fuller, G.N., Hook, M., Gelovani, J.G., Sidman, R.L., Cavenee, W.K., Pasqualini, R., Arap, W., Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 121 (2011), 161–173.
29. [29] Staquicini, F.I., Qian, M.D., Salameh, A., Dobroff, A.S., Edwards, J.K., Cimino, D.F., Moeller, B.J., Kelly, P., Nunez, M.I., Tang, X., Liu, D.D., Lee, J.J., Hong, W.K., Ferrara, F., Bradbury, A.R., Lobb, R.R., Edelman, M.J., Sidman, R.L., Wistuba, I.I., Arap, W., Pasqualini, R., Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. J. Biol. Chem. 290 (2015), 7345–7359.
30. [30] Tandle, A., Hanna, E., Lorang, D., Hajitou, A., Moya, C.A., Pasqualini, R., Arap, W., Adem, A., Starker, E., Hewitt, S., Libutti, S.K., Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer 115 (2009), 128–139.
31. [31] Trepel, M., Stoneham, C.A., Eleftherohorinou, H., Mazarakis, N.D., Pasqualini, R., Arap, W., Hajitou, A., A heterotypic bystander effect for tumor cell killing after adeno-associated virus/phage-mediated, vascular-targeted suicide gene transfer. Mol. Cancer Ther. 8 (2009), 2383–2391.
32. [32] Cossu, I., Bottoni, G., Loi, M., Emionite, L., Bartolini, A., Di Paolo, D., Brignole, C., Piaggio, F., Perri, P., Sacchi, A., Curnis, F., Gagliani, M.C., Bruno, S., Marini, C., Gori, A., Longhi, R., Murgia, D., Sementa, A.R., Cilli, M., Tacchetti, C., Corti, A., Sambuceti, G., Marchiò, S., Ponzoni, M., Pastorino, F., Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. Biomaterials 68 (2015), 89–99.
33. [33] Deshpande, P.P., Biswas, S., Torchilin, V.P., Current trends in the use of liposomes for tumor targeting. Nanomedicine 8 (2013), 1509–1528.
34. [34] Loi, M., Di Paolo, D., Soster, M., Brignole, C., Bartolini, A., Emionite, L., Sun, J., Becherini, P., Curnis, F., Petretto, A., Sani, M., Gori, A., Milanese, M., Gambini, C., Longhi, R., Cilli, M., Allen, T.M., Bussolino, F., Arap, W., Pasqualini, R., Corti, A., Ponzoni, M., Marchiò, S., Pastorino, F., Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. J. Control. Release 170 (2013), 233–241.
35. [35] Loi, M., Marchiò, S., Becherini, P., Di Paolo, D., Soster, M., Curnis, F., Brignole, C., Pagnan, G., Perri, P., Caffa, I., Longhi, R., Nico, B., Bussolino, F., Gambini, C., Ribatti, D., Cilli, M., Arap, W., Pasqualini, R., Allen, T.M., Corti, A., Ponzoni, M., Pastorino, F., Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J. Control. Release 145 (2010), 66–73.
36. [36] Gillespie, J.W., Gross, A.L., Puzyrev, A.T., Bedi, D., Petrenko, V.A., Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins. Front. Microbiol., 6, 2015, 628.
37. [37] Ashley, C.E., Carnes, E.C., Epler, K.E., Padilla, D.P., Phillips, G.K., Castillo, R.E., Wilkinson, D.C., Wilkinson, B.S., Burgard, C.A., Kalinich, R.M., Townson, J.L., Chackerian, B., Willman, C.L., Peabody, D.S., Wharton, W., Brinker, C.J., Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 6 (2012), 2174–2188.
38. [38] Ashley, C.E., Carnes, E.C., Phillips, G.K., Padilla, D., Durfee, P.N., Brown, P.A., Hanna, T.N., Liu, J., Phillips, B., Carter, M.B., Carroll, N.J., Jiang, X., Dunphy, D.R., WIllman, C.L., Petsev, D.N., Evans, D.G., Parikh, A.N., Chackerian, B., Warton, W., Peabody, D.S., Brinker, C.J., The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 10 (2011), 389–397.
39. [39] Liu, J., Stace-Naughton, A., Jiang, X., Brinker, C.J., Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. J. Am. Chem. Soc. 131 (2009), 1354–1355.
40. [40] Arap, W., Kolonin, M.G., Trepel, M., Lahdenranta, J., Cardó-Vila, M., Giordano, R.J., Mintz, P.J., Ardelt, P.U., Yao, V.J., Vidal, C.I., Chen, L., Flamm, A., Valtanen, H., Weavind, L.M., Hicks, M.E., Pollock, R.E., Botz, G.H., Bucana, C.D., Koivunen, E., Cahill, D., Troncoso, P., Baggerly, K.A., Pentz, R.D., Do, K.A., Logothetis, C.J., Pasqualini, R., Steps toward mapping the human vasculature by phage display. Nat. Med. 8 (2002), 121–127.
41. [41] Cardó-Vila, M., Zurita, A.J., Giordano, R.J., Sun, J., Rangel, R., Guzman-Rojas, L., Anobom, C.D., Valente, A.P., Almeida, F.C., Lahdenranta, J., Kolonin, M.G., Arap, W., Pasqualini, R., A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS One, 3, 2008, e3452.
42. [42] Zurita, A.J., Troncoso, P., Cardó-Vila, M., Logothetis, C.J., Pasqualini, R., Arap, W., Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res. 64 (2004), 435–439.
43. [43] Arap, M.A., Lahdenranta, J., Mintz, P.J., Hajitou, A., Sarkis, A.S., Arap, W., Pasqualini, R., Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6 (2004), 275–284.
44. [44] Lee, A.S., Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat. Rev. Cancer 14 (2014), 263–276.
45. [45] Mandelin, J., Cardó-Vila, M., Driessen, W.H., Mathew, P., Navone, N.M., Lin, S.H., Logothetis, C.J., Rietz, A.C., Dobroff, A.S., Proneth, B., Sidman, R.L., Pasqualini, R., Arap, W., Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 3776–3781.
46. [46] Mintz, P.J., Kim, J., Do, K.A., Wang, X., Zinner, R.G., Cristofanilli, M., Arap, M.A., Hong, W.K., Troncoso, P., Logothetis, C.J., Pasqualini, R., Arap, W., Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat. Biotechnol. 21 (2003), 57–63.
47. [47] Zhang, Y., Tseng, C.C., Tsai, Y.L., Fu, X., Schiff, R., Lee, A.S., Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One, 8, 2013, e80071.
48. [48] Bidard, F.C., Tredan, O., Trends in cancer-targeted antibody-drug conjugates. Target. Oncol. 9 (2014), 1–8.
49. [49] Morbeck, D.E., Roche, P.C., Keutmann, H.T., McCormick, D.J., A receptor binding site identified in the region 81–95 of the beta-subunit of human luteinizing hormone (LH) and chorionic gonadotropin (hCG). Mol. Cell. Endocrinol. 97 (1993), 173–181.
50. [50] Qayum, A., Gullick, W., Clayton, R.C., Sikora, K., Waxman, J., The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br. J. Cancer 62 (1990), 96–99.
51. [51] Hansel, W., Enright, F., Leuschner, C., Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol. Cell. Endocrinol. 260–262 (2007), 183–189.
52. [52] Hansel, W., Leuschner, C., Enright, F., Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol. Cell. Endocrinol. 269 (2007), 26–33.
53. [53] Sun, H., Zhu, X., Lu, P.Y., Rosato, R.R., Tan, W., Zu, Y., Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol. Ther. Nucleic Acids, 3, 2014, e182.
54. [54] Zhu, J., Huang, H., Dong, S., Ge, L., Zhang, Y., Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges. Theranostics 4 (2014), 931–944.
55. [55] Porciani, D., Tedeschi, L., Marchetti, L., Citti, L., Piazza, V., Beltram, F., Signore, G., Aptamer-mediated codelivery of doxorubicin and NF-kappaB decoy enhances chemosensitivity of pancreatic tumor cells. Mol. Ther. Nucleic Acids, 4, 2015, e235.
56. [56] Fujimori, K., Covell, D.G., Fletcher, J.E., Weinstein, J.N., Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab’)2, and Fab in tumors. Cancer Res. 49 (1989), 5656–5663.
57. [57] Pascal, J., Ashley, C.E., Wang, Z., Brocato, T.A., Butner, J.D., Carnes, E.C., Koay, E.J., Brinker, C.J., Cristini, V., Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. ACS Nano 7 (2013), 11174–11182.
58. [58] Smith, G.P., Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 (1985), 1315–1317.
59. [59] Pasqualini, R., Koivunen, E., Ruoslahti, E., Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15 (1997), 542–546.
60. [60] Rajotte, D., Arap, W., Hagedorn, M., Koivunen, E., Pasqualini, R., Ruoslahti, E., Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102 (1998), 430–437.
61. [61] Kolonin, M.G., Pasqualini, R., Arap, W., Teratogenicity induced by targeting a placental immunoglobulin transporter. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 13055–13060.
62. [62] Trepel, M., Arap, W., Pasqualini, R., In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr. Opin. Chem. Biol. 6 (2002), 399–404.
63. [63] Barnhart, K.F., Christianson, D.R., Hanley, P.W., Driessen, W.H., Bernacky, B.J., Baze, W.B., Wen, S., Tian, M., Ma, J., Kolonin, M.G., Saha, P.K., Do, K.A., Hulvat, J.F., Gelovani, J.G., Chan, L., Arap, W., Pasqualini, R., A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci. Transl. Med., 3, 2011, 108ra112.
64. [64] Giordano, R.J., Lahdenranta, J., Zhen, L., Chukwueke, U., Petrache, I., Langley, R.R., Fidler, I.J., Pasqualini, R., Tuder, R.M., Arap, W., Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse. J. Biol. Chem. 283 (2008), 29447–29460.
65. [65] Koivunen, E., Gay, D.A., Ruoslahti, E., Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J. Biol. Chem. 268 (1993), 20205–20210.
66. [66] Pentz, R.D., Flamm, A.L., Pasqualini, R., Logothetis, C.J., Arap, W., Revisiting ethical guidelines for research with terminal wean and brain-dead participants. Hast. Cent. Rep. 33 (2003), 20–26.
67. [67] Yao, V.J., Ozawa, M.G., Trepel, M., Arap, W., McDonald, D.M., Pasqualini, R., Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am. J. Pathol. 166 (2005), 625–636.
68. [68] Grant, J.A., Gallardo, M.A., Pickup, B., A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape. J. Comput. Chem. 17 (1996), 1653–1666.
69. [69] Oprea, T.I., Gottfries, J., Chemography: the art of navigating in chemical space. J. Comb. Chem. 3 (2001), 157–166.
70. [70] Ung, P., Winkler, D.A., Tripeptide motifs in biology: targets for peptidomimetic design. J. Med. Chem. 54 (2011), 1111–1125.
71. [71] Vendruscolo, M., Paci, E., Dobson, C.M., Karplus, M., Three key residues form a critical contact network in a protein folding transition state. Nature 409 (2001), 641–645.
72. [72] Christianson, D.R., Ozawa, M.G., Pasqualini, R., Arap, W., Techniques to decipher molecular diversity by phage display. Methods Mol. Biol. 357 (2007), 385–406.
73. [73] Dondossola, E., Corti, A., Sidman, R.L., Arap, W., Pasqualini, R., Bone marrow-derived CD13 cells sustain tumor progression: a potential non-malignant target for anticancer therapy. Oncoimmunology, 3, 2014, e27716.
74. [74] Dondossola, E., Rangel, R., Guzman-Rojas, L., Barbu, E.M., Hosoya, H., John, L.S.S., Molldrem, J.J., Corti, A., Sidman, R.L., Arap, W., Pasqualini, R., CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 20717–20722.
75. [75] Guzman-Rojas, L., Rangel, R., Salameh, A., Edwards, J.K., Dondossola, E., Kim, Y.G., Saghatelian, A., Giordano, R.J., Kolonin, M.G., Staquicini, F.I., Koivunen, E., Sidman, R.L., Arap, W., Pasqualini, R., Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 1637–1642.
76. [76] Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R.A., Shapiro, L.H., Arap, W., Ruoslahti, E., Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60 (2000), 722–727.
77. [77] Cardó-Vila, M., Giordano, R.J., Sidman, R.L., Bronk, L.F., Fan, Z., Mendelsohn, J., Arap, W., Pasqualini, R., From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 5118–5123.
78. [78] Giordano, R.J., Cardó-Vila, M., Salameh, A., Anobom, C.D., Zeitlin, B.D., Hawke, D.H., Valente, A.P., Almeida, F.C., Nor, J.E., Sidman, R.L., Pasqualini, R., Arap, W., From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 5112–5117.
79. [79] Pang, H.B., Braun, G.B., She, Z.G., Kotamraju, V.R., Sugahara, K.N., Teesalu, T., Ruoslahti, E., A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. J. Control. Release 175 (2014), 48–53.
80. [80] Sidman, R.L., Li, J., Lawrence, M., Hu, W., Musso, G.F., Giordano, R.J., Cardó-Vila, M., Pasqualini, R., Arap, W., The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. Sci. Transl. Med., 7, 2015, 309ra165.
81. [81] Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Girard, O.M., Hanahan, D., Mattrey, R.F., Ruoslahti, E., Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16 (2009), 510–520.
82. [82] Wang, S., Placzek, W.J., Stebbins, J.L., Mitra, S., Noberini, R., Koolpe, M., Zhang, Z., Dahl, R., Pasquale, E.B., Pellecchia, M., Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J. Med. Chem. 55 (2012), 2427–2436.
83. [83] Christianson, D.R., Dobroff, A.S., Proneth, B., Zurita, A.J., Salameh, A., Dondossola, E., Makino, J., Bologa, C.G., Smith, T.L., Yao, V.J., Calderone, T.L., O'Connell, D.J., Oprea, T.I., Kataoka, K., Cahill, D.J., Gershenwald, J.E., Sidman, R.L., Arap, W., Pasqualini, R., Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 2521–2526.
84. [84] Marchiò, S., Lahdenranta, J., Schlingemann, R.O., Valdembri, D., Wesseling, P., Arap, M.A., Hajitou, A., Ozawa, M.G., Trepel, M., Giordano, R.J., Nanus, D.M., Dijkman, H.B., Oosterwijk, E., Sidman, R.L., Cooper, M.D., Bussolino, F., Pasqualini, R., Arap, W., Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 5 (2004), 151–162.
85. [85] Mintz, P.J., Rietz, A.C., Cardó-Vila, M., Ozawa, M.G., Dondossola, E., Do, K.A., Kim, J., Troncoso, P., Logothetis, C.J., Sidman, R.L., Pasqualini, R., Arap, W., Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 2515–2520.
86. [86] Mintz, P.J., Cardó-Vila, M., Ozawa, M.G., Hajitou, A., Rangel, R., Guzman-Rojas, L., Christianson, D.R., Arap, M.A., Giordano, R.J., Souza, G.R., Easley, J., Salameh, A., Oliviero, S., Brentani, R.R., Koivunen, E., Arap, W., Pasqualini, R., An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 2182–2187.
87. [87] Yao, V.J., Ozawa, M.G., Varner, A.S., Kasman, I.M., Chanthery, Y.H., Pasqualini, R., Arap, W., McDonald, D.M., Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res. 66 (2006), 2639–2649.
88. [88] Giordano, R.J., Cardó-Vila, M., Lahdenranta, J., Pasqualini, R., Arap, W., Biopanning and rapid analysis of selective interactive ligands. Nat. Med. 7 (2001), 1249–1253.
89. [89] Kuijper, S., Turner, C.J., Adams, R.H., Regulation of angiogenesis by Eph–ephrin interactions. Trends Cardiovasc. Med. 17 (2007), 145–151.
90. [90] Gu, C., Liu, L., He, Y., Jiang, J., Yang, Z., Wu, Q., The binding characteristics of a cyclic nonapeptide, c(CGRRAGGSC), in LNCaP human prostate cancer cells. Oncol. Lett. 4 (2012), 443–449.
91. [91] Wang, W., Ke, S., Kwon, S., Yallampalli, S., Cameron, A.G., Adams, K.E., Mawad, M.E., Sevick-Muraca, E.M., A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug. Chem. 18 (2007), 397–402.
92. [92] Hanavadi, S., Martin, T.A., Watkins, G., Mansel, R.E., Jiang, W.G., Expression of interleukin 11 and its receptor and their prognostic value in human breast cancer. Ann. Surg. Oncol. 13 (2006), 802–808.
93. [93] Javadpour, M.M., Juban, M.M., Lo, W.C., Bishop, S.M., Alberty, J.B., Cowell, S.M., Becker, C.L., McLaughlin, M.L., De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem. 39 (1996), 3107–3113.
94. [94] Ellerby, H.M., Arap, W., Ellerby, L.M., Kain, R., Andrusiak, R., Rio, G.D., Krajewski, S., Lombardo, C.R., Rao, R., Ruoslahti, E., Bredesen, D.E., Pasqualini, R., Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5 (1999), 1032–1038.
95. [95] Lewis, V.O., Ozawa, M.G., Deavers, M.T., Wang, G., Shintani, T., Arap, W., Pasqualini, R., The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples. Cancer Res. 69 (2009), 1995–1999.
96. [96] Li, Z.G., Mathew, P., Yang, J., Starbuck, M.W., Zurita, A.J., Liu, J., Sikes, C., Multani, A.S., Efstathiou, E., Lopez, A., Wang, J., Fanning, T.V., Prieto, V.G., Kundra, V., Vazquez, E.S., Troncoso, P., Raymond, A.K., Logothetis, C.J., Lin, S.H., Maity, S., Navone, N.M., Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J. Clin. Invest. 118 (2008), 2697–2710.
97. [97] Sato, M., Yao, V.J., Arap, W., Pasqualini, R., GRP78 signaling hub a receptor for targeted tumor therapy. Adv. Genet. 69 (2010), 97–114.
98. [98] Lee, A.S., Bell, J., Ting, J., Biochemical characterization of the 94- and 78-kilodalton glucose-regulated proteins in hamster fibroblasts. J. Biol. Chem. 259 (1984), 4616–4621.
99. [99] Cox, J.S., Shamu, C.E., Walter, P., Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 73 (1993), 1197–1206.
100. 2 +/CDC28-related kinase activity is required for signaling from the ER to the nucleus. Cell 74 (1993), 743–756.
101. [101] Blond-Elguindi, S., Cwirla, S.E., Dower, W.J., Lipshutz, R.J., Sprang, S.R., Sambrook, J.F., Gething, M.J., Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP. Cell 75 (1993), 717–728.
102. [102] Dong, D., Ko, B., Baumeister, P., Swenson, S., Costa, F., Markland, F., Stiles, C., Patterson, J.B., Bates, S.E., Lee, A.S., Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res. 65 (2005), 5785–5791.
103. [103] Lee, A.S., The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 35 (2005), 373–381.
104. [104] Daneshmand, S., Quek, M.L., Lin, E., Lee, C., Cote, R.J., Hawes, D., Cai, J., Groshen, S., Lieskovsky, G., Skinner, D.G., Lee, A.S., Pinski, J., Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum. Pathol. 38 (2007), 1547–1552.
105. [105] Fu, Y., Li, J., Lee, A.S., GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 67 (2007), 3734–3740.
106. [106] Gonzalez-Gronow, M., Cuchacovich, M., Llanos, C., Urzua, C., Gawdi, G., Pizzo, S.V., Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res. 66 (2006), 11424–11431.
107. [107] Reichert, J.M., Antibodies to watch in 2015. mAbs 7 (2015), 1–8.
108. [108] Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V., Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000), 443–446.
109. [109] Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., Janakiraman, N., Foon, K.A., Liles, T.M., Dallaire, B.K., Wey, K., Royston, I., Davis, T., Levy, R., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997), 2188–2195.
110. [110] Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004), 391–400.
111. [111] Sliwkowski, M.X., Mellman, I., Antibody therapeutics in cancer. Science 341 (2013), 1192–1198.
112. [112] Baselga, J., Gelmon, K.A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V.A., Ross, G.A., Fumoleau, P., Gianni, L., Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28 (2010), 1138–1144.
113. [113] Mack, F., Ritchie, M., Sapra, P., The next generation of antibody drug conjugates. Semin. Oncol. 41 (2014), 637–652.
114. [114] Lewis Phillips, G.D., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E., Blattler, W.A., Lambert, J.M., Chari, R.V., Lutz, R.J., Wong, W.L., Jacobson, F.S., Koeppen, H., Schwall, R.H., Kenkare-Mitra, S.R., Spencer, S.D., Sliwkowski, M.X., Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68 (2008), 9280–9290.
115. [115] Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., Burke, M.M., Caldwell, A., Kronenberg, S.A., Agunwamba, B.U., Zhang, X., Lowy, I., Inzunza, H.D., Feely, W., Horak, C.E., Hong, Q., Korman, A.J., Wigginton, J.M., Gupta, A., Sznol, M., Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
116. [116] Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
117. [117] List, T., Neri, D., Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin. Pharmacol. 5 (2013), 29–45.
118. [118] Alewine, C., Hassan, R., Pastan, I., Advances in anticancer immunotoxin therapy. Oncologist 20 (2015), 176–185.
119. [119] Kohler, G., Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975), 495–497.
120. [120] Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S., Winter, G., Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986), 522–525.
121. [121] Doerner, A., Rhiel, L., Zielonka, S., Kolmar, H., Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett. 588 (2014), 278–287.
122. [122] Nixon, A.E., Sexton, D.J., Ladner, R.C., Drugs derived from phage display: from candidate identification to clinical practice. mAbs 6 (2014), 73–85.
123. [123] Carter, P.J., Potent antibody therapeutics by design. Nat. Rev. Immunol. 6 (2006), 343–357.
124. [124] Jakobovits, A., Amado, R.G., Yang, X., Roskos, L., Schwab, G., From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 25 (2007), 1134–1143.
125. [125] Huston, J.S., Levinson, D., Mudgett-Hunter, M., Tai, M.S., Novotny, J., Margolies, M.N., Ridge, R.J., Bruccoleri, R.E., Haber, E., Crea, R., et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 85 (1988), 5879–5883.
126. [126] Griffiths, A.D., Williams, S.C., Hartley, O., Tomlinson, I.M., Waterhouse, P., Crosby, W.L., Kontermann, R.E., Jones, P.T., Low, N.M., Allison, T.J., et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13 (1994), 3245–3260.
127. [127] Decanniere, K., Desmyter, A., Lauwereys, M., Ghahroudi, M.A., Muyldermans, S., Wyns, L., A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure 7 (1999), 361–370.
128. [128] Frenzel, A., Hust, M., Schirrmann, T., Expression of recombinant antibodies. Front. Immunol., 4, 2013, 217.
129. [129] Worn, A., Pluckthun, A., Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 37 (1998), 13120–13127.
130. [130] Glanville, J., Zhai, W., Berka, J., Telman, D., Huerta, G., Mehta, G.R., Ni, I., Mei, L., Sundar, P.D., Day, G.M., Cox, D., Rajpal, A., Pons, J., Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 20216–20221.
131. [131] Marks, J.D., Hoogenboom, H.R., Bonnert, T.P., McCafferty, J., Griffiths, A.D., Winter, G., By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222 (1991), 581–597.
132. [132] Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., Virnekas, B., Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296 (2000), 57–86.
133. [133] Birtalan, S., Zhang, Y., Fellouse, F.A., Shao, L., Schaefer, G., Sidhu, S.S., The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J. Mol. Biol. 377 (2008), 1518–1528.
134. [134] Sblattero, D., Lou, J., Marzari, R., Bradbury, A., In vivo recombination as a tool to generate molecular diversity in phage antibody libraries. J. Biotechnol. 74 (2001), 303–315.
135. [135] Clackson, T., Hoogenboom, H.R., Griffiths, A.D., Winter, G., Making antibody fragments using phage display libraries. Nature 352 (1991), 624–628.
136. [136] Hanes, J., Schaffitzel, C., Knappik, A., Pluckthun, A., Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18 (2000), 1287–1292.
137. [137] Boder, E.T., Wittrup, K.D., Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15 (1997), 553–557.
138. [138] Feldhaus, M.J., Siegel, R.W., Yeast display of antibody fragments: a discovery and characterization platform. J. Immunol. Methods 290 (2004), 69–80.
139. [139] Swers, J.S., Kellogg, B.A., Wittrup, K.D., Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res., 32, 2004, e36.
140. [140] Glanville, J., D'Angelo, S., Khan, T.A., Reddy, S.T., Naranjo, L., Ferrara, F., Bradbury, A., Deep sequencing in library selection projects: what insight does it bring?. Curr. Opin. Struct. Biol. 33 (2015), 146–160.
141. [141] Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986), 6387–6392.
142. [142] Adams, G.P., Schier, R., Marshall, K., Wolf, E.J., McCall, A.M., Marks, J.D., Weiner, L.M., Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58 (1998), 485–490.
143. [143] Adams, G.P., Schier, R., McCall, A.M., Simmons, H.H., Horak, E.M., Alpaugh, R.K., Marks, J.D., Weiner, L.M., High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61 (2001), 4750–4755.
144. [144] Rudnick, S.I., Lou, J., Shaller, C.C., Tang, Y., Klein-Szanto, A.J., Weiner, L.M., Marks, J.D., Adams, G.P., Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res. 71 (2011), 2250–2259.
145. [145] Schmidt, M.M., Wittrup, K.D., A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 8 (2009), 2861–2871.
146. [146] Zahnd, C., Kawe, M., Stumpp, M.T., de Pasquale, C., Tamaskovic, R., Nagy-Davidescu, G., Dreier, B., Schibli, R., Binz, H.K., Waibel, R., Pluckthun, A., Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res. 70 (2010), 1595–1605.
147. [147] Adams, G.P., Schier, R., McCall, A.M., Crawford, R.S., Wolf, E.J., Weiner, L.M., Marks, J.D., Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77 (1998), 1405–1412.
148. [148] Cuesta, A.M., Sainz-Pastor, N., Bonet, J., Oliva, B., Alvarez-Vallina, L., Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 28 (2010), 355–362.
149. [149] McCall, A.M., Shahied, L., Amoroso, A.R., Horak, E.M., Simmons, H.H., Nielson, U., Adams, G.P., Schier, R., Marks, J.D., Weiner, L.M., Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J. Immunol. 166 (2001), 6112–6117.
150. [150] Schmidt, M.M., Thurber, G.M., Wittrup, K.D., Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol. Immunother. 57 (2008), 1879–1890.
151. [151] Liu, B., Conrad, F., Cooperberg, M.R., Kirpotin, D.B., Marks, J.D., Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 64 (2004), 704–710.
152. [152] Poul, M.A., Becerril, B., Nielsen, U.B., Morisson, P., Marks, J.D., Selection of tumor-specific internalizing human antibodies from phage libraries. J. Mol. Biol. 301 (2000), 1149–1161.
153. [153] Zhou, Y., Zou, H., Zhang, S., Marks, J.D., Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J. Mol. Biol. 404 (2010), 88–99.
154. [154] D'Angelo, S., Glanville, J., Ferrara, F., Naranjo, L., Gleasner, C.D., Shen, X., Bradbury, A.R., Kiss, C., The antibody mining toolbox: an open source tool for the rapid analysis of antibody repertoires. mAbs 6 (2014), 160–172.
155. [155] Reddy, L.H., Arias, J.L., Nicolas, J., Couvreir, P., Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 112 (2012), 5818–5878.
156. [156] Park, J.W., Bae, K.H., Kim, C., Park, T.G., Clustered magnetite nanocrystals cross-linked with PEI for efficient siRNA delivery. Biomacromolecules 12 (2011), 457–465.
157. [157] Kunzmann, A., Andersson, B., Thurnherr, T., Krug, H., Scheynius, A., Fadeel, B., Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim. Biophys. Acta 1810 (2011), 361–373.
158. [158] Boisselier, E., Astruc, D., Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev. 38 (2009), 1759–1782.
159. [159] Draz, M.S., Fang, B.A., Zhang, P., Hu, Z., Gu, S., Weng, K.C., Gray, J.W., Chen, F.F., Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 4 (2014), 872–892.
160. [160] Khlebtsov, N., Bogatyrev, V., Dykman, L., Khlebtsov, B., Staroverov, S., Shirokov, A., Matora, L., Khanadeev, V., Pylaev, T., Tsyganova, N., Ter-entyuk, G., Analytical and theranostic applications of gold nanoparticles and multifunctional nanocomposites. Theranostics 3 (2013), 167–180.
161. [161] Tong, L., Zhao, M., Zhu, S., Chen, J., Synthesis and application of superparamagnetic iron oxide nanoparticles in targeted therapy and imaging of cancer. Front. Med. 5 (2011), 379–387.
162. [162] Wang, Y.X., Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging Med. Surg. 1 (2011), 35–40.
163. [163] Khlebtsov, B., Dykman, L., Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem. Soc. Rev. 40 (2011), 1647–1671.
164. [164] Mejías, R., Gutiérrez, L., Salas, G., Pérez-Yagüe, S., Zotes, T.M., Lázaro, F.J., Morales, M.P., Barber, D.F., Long term biotransformation and toxicity of dimercaptosuccinic acid-coated magnetic nanoparticles support their use in biomedical applications. J. Control. Release 171 (2013), 225–233.
165. [165] Mahmoudi, M., Hofmann, H., Rothen-Ritishauser, B., Petri-Fink, A., Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem. Rev. 112 (2012), 2323–2338.
166. [166] Wang, L., Li, Y.-F., Zhao, L., Liu, Y., Meng, L., Zhang, K., Wu, X., Zhang, L., Li, B., Chen, C., Characterization of gold nanorods in vivo by integrated analytical techniques: their uptake, retention, and chemical forms. Anal. Bioanal. Chem. 396 (2010), 1105–1114.
167. [167] Goel, R., Shah, N., Visaria, R., Paciotti, G.F., Bischof, J.C., Biodistribution of TNF-α-coated gold nanoparticles in an in vivo model system. Nanomedicine 4 (2009), 401–410.
168. [168] Jensen, S.A., Day, E.S., Ko, C.H., Hurley, L.A., Luciano, J.P., Kouri, F.M., Merkel, T.J., Luthi, A.J., Patel, P.C., Cutler, J.I., Daniel, W.L., Scott, A.W., Rotz, M.W., Meade, T.J., Giljohann, D.A., Mirkin, C.A., Stegh, A.H., Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl. Med., 5, 2013, 209ra152.
169. [169] Ali-Boucetta, H., Kosarelos, K., Pharmacology of carbon nanotubes:toxicokinetics, excretion and tissue accumulation. Adv. Drug Deliv. Rev. 65 (2013), 2111–2119.
170. [170] Schipper, M.L., Nakayama-Ratchford, N., Davis, C.R., Kam, N.W.S., Chu, P., Liu, Z., Sun, X., Dai, H., Gambhir, S.S., A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat. Nanotechnol. 3 (2008), 216–221.
171. [171] Seabra, A.B., Paula, A.J., de Lima, R., Alves, O.L., Dura, N., Nanotoxicity of graphene and graphene oxide. Chem. Res. Toxicol. 27 (2014), 159–168.
172. [172] Chou, C.-C., Hsiao, H.-Y., Hong, Q.-S., Chen, C.-H., Peng, Y.-W., Chen, H.-W., Yang, P.-C., Single-walled carbon nanotubes can induce pulmonary injury in mouse model. Nano Lett. 8 (2008), 437–445.
173. [173] Liu, J.-H., Yang, S.-T., Wang, X., Wang, H., Liu, Y., Luo, P.G., Liu, Y., Sun, Y.-P., Carbon nanoparticles trapped in vivo-similar to carbon nanotubes in time-dependent biodistribution. ACS Appl. Mater. Interfaces 6 (2014), 14672–14678.
174. [174] Mitchell, L.A., Lauer, F.T., Burchiel, S.W., McDonald, J.D., Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat. Nanotechnol. 4 (2009), 451–456.
175. [175] Poland, C.A., Duffin, R., Kinloch, I., Maynard, A., Wallace, W.A.H., Seaton, A., Stone, V., Brown, S., MacNee, W., Donaldson, K., Carbon nanotubes introduced into the abdominal cavity of mice show asbestoslike pathogenicity in a pilot study. Nat. Nanotechnol. 3 (2008), 423–428.
176. [176] Tarn, D., Ashley, C.E., Xue, M., Carnes, E.C., Zink, J.I., Brinker, C.J., Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. Acc. Chem. Res. 46 (2013), 792–801.
177. [177] Du, L., Liao, S.J., Khatib, H.A., Stoddart, J.F., Zink, J.I., Controlled-access hollow mechanized silica nanocontainers. J. Am. Chem. Soc. 131 (2009), 15136–15142.
178. [178] Huang, X., Li, L., Liu, T., Hao, N., Liu, H., Chen, D., Tang, F., The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 5 (2011), 5390–5399.
179. [179] Lu, Y., Fan, H., Stump, A., Ward, T.L., Rieker, T., Brinker, C.J., Aerosol-assisted self-assembly of mesostructured spherical nanoparticles. Nature 398 (1999), 223–226.
180. [180] Han, L., Zhou, Y., He, T., Song, G., Wu, F., Jiang, F., Hu, J., One-pot morphology-controlled synthesis of various shaped mesoporous silica nanoparticles. J. Mater. Sci. 48 (2013), 5718–5726.
181. [181] Meng, H., Yang, S., Li, Z., Xia, T., Chen, J., Ji, Z., Zhang, H., Wang, X., Lin, S., Huang, C., Zhou, H., Zink, J.I., Nel, A.E., Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS Nano 5 (2011), 4434–4447.
182. [182] Trewyn, B.G., Nieweg, J.A., Zhao, Y., Lin, V.S.-Y., Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane penetration. Chem. Eng. J. 137 (2008), 23–29.
183. [183] Xiong, L., Du, X., Shi, B., Bi, J., Kleitz, F., Qiao, S.Z., Tunable stellate mesoporous silica nanoparticles for intracellular drug delivery. J. Mater. Chem. B 3 (2015), 1712–1721.
184. [184] Du, X., Qiao, S.Z., Dendritic silica particles with center-radial pore channels: promising platforms for catalysis and biomedical applications. Small 11 (2015), 392–413.
185. [185] Huh, S., Wiench, J.W., Yoo, J.-C., Pruski, M., Lin, V.S.-Y., Organic functionalization and morphology control of mesoporous silicas via a co-condensation synthesis method. Chem. Mater. 15 (2003), 4247–4256.
186. [186] Nandiyanto, A.B.D., Kim, S.-G., Iskandar, F., Okuyama, K., Synthesis of spherical mesoporous silica nanoparticles with nanometer-size controllable pores and outer diameters. Microporous Mesoporous Mater. 120 (2009), 447–453.
187. [187] Phillips, E., Penate-Medina, O., Zanzonico, P.B., Carvajal, R.D., Mohan, P., Ye, Y., Humm, J., Gonen, M., Kalaigian, H., Schoder, H., Strauss, H.W., Larson, S.M., Wiesner, U., Bradbury, M.S., Clinical translation of an ultrasmall iorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med., 6, 2014 (260ra149).
188. [188] He, Q., Zhang, Z., Gao, Y., Shi, J., Li, Y., Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. Small 5 (2009), 2722–2729.
189. [189] He, L., Lai, H., Chen, T., Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways. Biomaterials 51 (2015), 30–42.
190. [190] Lu, J., Liong, M., Li, Z., Zink, J.I., Tamanoi, F., Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6 (2010), 1794–1805.
191. [191] Souris, J.S., Lee, C.-H., Cheng, S.-H., Chen, C.-T., Yang, C.-S., Ho, J.A., Mou, C.-Y., Lo, L.-W., Surface charge-mediate rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 31 (2010), 5564–5574.
192. [192] Fu, C., Liu, T., Li, L., Liu, H., Chen, D., Tang, F., The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials 34 (2013), 2565–2575.
193. [193] He, Q., Zhang, Z., Gao, F., Li, Y., Shi, J., In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small 7 (2011), 271–280.
194. [194] Wang, L.-S., Wu, L.-C., Lu, S.-Y., Chang, L.-L., Teng, I.T., Yang, C.-M., Ho, J.-A.A., Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS Nano 4 (2010), 4371–4379.
195. [195] Allen, T.M., Cullis, P.R., Drug delivery systems: entering the mainstream. Science 303 (2004), 1818–1822.
196. [196] Egusquiguirre, S.P., Igartua, M., Hernandez, R.M., Pedraz, J.L., Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin. Transl. Oncol. 14 (2012), 83–93.
197. [197] Iwamoto, T., Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol. Pharm. Bull. 36 (2013), 715–718.
198. [198] Davis, M.E., Chen, Z., Shin, D.M., Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7 (2008), 771–782.
199. [199] Farokhzad, O.C., Langer, R., Impact of nanotechnology on drug delivery. ACS Nano 3 (2009), 16–20.
200. [200] Peer, D., Karp, J.M., Hong, S., Farokhzad, O.C., Margalit, R., Langer, R., Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007), 751–760.
201. [201] Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005), 145–160.
202. [202] Reynolds, J.G., Geretti, E., Hendriks, B.S., Lee, H., Leonard, S.C., Klinz, S.G., Noble, C.O., Lücker, P.B., Zandstra, P.W., Drummond, D.C., Olivier, K.J. Jr., Nielsen, U.B., Niyikiza, C., Agresta, S.V., Wickham, T.J., HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol. Appl. Pharmacol. 262 (2012), 1–10.
203. [203] Sapra, P., Allen, T.M., Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42 (2003), 439–462.
204. [204] Drummond, D.C., Noble, C.O., Guo, Z., Hayes, M.E., Connolly-Ingram, C., Gabriel, B.S., Hann, B., Liu, B., Park, J.W., Hong, K., Benz, C.C., Marks, J.D., Kirpotin, D.B., Development of a highly stable and targetable nanoliposomal formulation of topotecan. J. Control. Release 141 (2010), 13–21.
205. [205] Noble, C.O., Guo, Z., Hayes, M.E., Marks, J.D., Park, J.W., Benz, C.C., Kirpotin, D.B., Drummond, D.C., Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother. Pharmacol. 64 (2009), 741–751.
206. [206] Batist, G., Ramakrishnan, G., Rao, C.S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M.K., Hoelzer, K., Tkaczuk, K., Park, Y.C., Lee, L.W., Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 19 (2001), 1444–1454.
207. [207] Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., Group, T.D.S., Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94 (2002), 25–36.
208. [208] Northfelt, D.W., Dezube, B.J., Thommes, J.A., Miller, B.J., Fischl, M.A., Friedman-Kien, A., Kaplan, L.D., Mond, C. Du, Mamelok, R.D., Henry, D.H., Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 16 (1998), 2445–2451.
209. [209] O'Brien, M.E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L., Tendler, C., Group, C.B.C.S., Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (2004), 440–449.
210. [210] Stathopoulos, G.P., Boulikas, T., Lipoplatin formulation review article. J. Drug Deliv., 2012, 2012, 581363.
211. [211] Zamboni, W.C., Ramalingam, S., Friedland, D.M., Edwards, R.P., Stoller, R.G., Strychor, S., Maruca, L., Zamboni, B.A., Belani, C.P., Ramanathan, R.K., Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin. Cancer Res. 15 (2009), 1466–1472.
212. [212] Batist, G., Gelmon, K.A., Chi, K.N., Miller, W.H. Jr., Chia, S.K., Mayer, L.D., Swenson, C.E., Janoff, A.S., Louie, A.C., Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15 (2009), 692–700.
213. [213] Liang, Z., Yang, N., Jiang, Y., Hou, C., Zheng, J., Shi, J., Zhang, R., Li, D., Liu, Y., Zuo, P., Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer. Int. J. Pharm. 494 (2015), 337–345.
214. [214] Kirpotin, D.B., Noble, C.O., Hayes, M.E., Huang, Z., Kornaga, T., Zhou, Y., Nielsen, U.B., Marks, J.D., Drummond, D.C., Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 502 (2012), 139–166.
215. [215] Laukkanen, M.L., Teeri, T.T., Keinanen, K., Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. Protein Eng. 6 (1993), 449–454.
216. [216] Park, J.W., Hong, K., Kirpotin, D.B., Meyer, O., Papahadjopoulos, D., Benz, C.C., Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 118 (1997), 153–160.
217. [217] de Kruif, J., Storm, G., van Bloois, L., Logtenberg, T., Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett. 399 (1996), 232–236.
218. [218] Williford, J.-M., Wu, J., Ren, Y., Archang, M.M., Leong, K.W., Mao, H.-Q., Recent advances in nanoparticle-mediated siRNA delivery. Annu. Rev. Biomed. Eng. 16 (2014), 347–370.
219. [219] Irvine, D.J., One nanoparticle, one kill. Nat. Mater. 10 (2011), 342–343.
220. [220] Stark, B., Pabst, G., Prassl, R., Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure. Eur. J. Pharm. Sci. 41 (2010), 546–555.
221. [221] Amstad, E., Kohlbrecher, J., Muller, E., Schweizer, T., Textor, M., Reimhult, E., Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containing membranes. Nano Lett. 11 (2011), 1664–1670.
222. [222] Cauda, V., Engelke, H., Sauer, A., Arcizet, D., Bräuchle, C., Rädler, J., Bein, T., Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. Nano Lett. 10 (2010), 2484–2492.
223. [223] Chen, B., Liu, M., Zhang, L., Huang, J., Yao, J., Zhang, Z., Polyethylenimine-functionalized graphene oxide as an efficient gene delivery vector. J. Mater. Chem. 21 (2011), 7736–7741.
224. [224] Epler, K., Padilla, D., Phillips, G., Crowder, P., Castillo, R., WIlkinson, D., WIlkinson, B., Burgard, C., Kalinich, R., Townson, J., Chackerian, B., Willman, C., Peabody, D., Wharton, W., Brinker, C.J., Ashley, C., Carnes, E., Delivery of ricin toxin a-chain by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. Adv. Healthcare Mater. 1 (2012), 348–353.
225. [225] Feng, L., Zhang, S., Zhuang, L., Graphene based gene transfection. Nanoscale 3 (2011), 1252–1257.
226. [226] Kim, H., Namgung, R., Singha, K., Oh, I.-K., Kim, W.J., Graphene oxide-polyethylenimine nanoconstruct as a gene delivery vector and bioimaging tool. Bioconjug. Chem. 22 (2011), 2558–2567.
227. [227] Liu, L., Wei, Y., Zhai, S., Chen, Q., Xing, D., Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy. Biomaterials 62 (2015), 35–46.
228. [228] Mattingly, S.J., O'Toole, M., James, K.T., Clark, G.J., Nantz, M.H., Magnetic nanoparticle-supported lipid bilayers for drug delivery. Langmuir 31 (2015), 3326–3332.
229. 2 nanobeads. Langmuir 26 (2010), 12081–12088.
230. 4-graphene as an amphiphilic drug carrier for thermo-chemotherapy of cancer. Appl. Mater. Interfaces 7 (2015), 8013–8022.
231. [231] Tam, N.C.M., Scott, B.M.T., Voicu, D., Wilson, B.C., Zheng, G., Facile synthesis of raman active phospholipid gold nanoparticles. Bioconjug. Chem. 21 (2010), 2178–2182.
232. [232] Scarberry, K.E., Dickerson, E.B., McDonald, J.F., Zhang, Z.J., Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J. Am. Chem. Soc. 130 (2008), 10258–10262.
233. [233] Chen, Y., Yang, W., Chang, B., Hua, H., Fang, X., Sha, X., In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation. Eur. J. Pharm. Biopharm. 85 (2013), 406–412.
234. [234] Meng, H., Xue, M., Xia, T., Ji, Z., Tarn, D.Y., Zink, J.I., Nel, A.E., Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 5 (2011), 4131–4144.
235. [235] Li, L., Tang, F., Liu, H., Liu, T., Hao, N., Chen, D., Teng, X., He, J., In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 4 (2010), 6874–6882.
236. [236] Meng, H., Zhao, Y., Dong, J., Xue, M., Lin, Y.-S., Ji, Z., Mai, W.X., Zhang, H., Chang, C.H., Brinker, C.J., Zink, J.I., Nel, A.E., Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano 7 (2013), 10048–10065.
237. [237] Hwang, A.A., Lu, J., Tamanoi, F., Zink, J.I., Functional nanovavles on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small 11 (2015), 319–328.
238. [238] Lu, J., Li, Z., Zink, J.I., Tamanoi, F., In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine: NBM 8 (2012), 212–220.
239. [239] Lin, Y.-S., Haynes, C.L., Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J. Am. Chem. Soc. 132 (2010), 4834–4842.
240. [240] Han, N., Zhao, Q., Wan, L., Wang, Y., Gao, Y., Wang, P., Wang, Z., Zhang, J., Jiang, T., Wang, S., Hybrid lipid-capped mesoporous silica for stimuli-resposive drug release and overcoming multidrug resistance. Appl. Mater. Interfaces 7 (2015), 3342–3351.
241. [241] Mackowiak, S.A., Schmidt, A., Weiss, V., Argyo, C., von Schirnding, C., Bein, T., Bräuchle, C., Targeted drug delivery in cancer cells with red-light photoactivated mesoporous silica nanoparticles. Nano Lett. 13 (2013), 2576–2583.
242. [242] Meng, H., Wang, M., Liu, H., Liu, X., Situ, A., Wu, B., Ji, Z., Chang, C.H., Nel, A.E., Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano 9 (2015), 3540–3557.
243. [243] Porotto, M., Yi, F., Moscona, A., LaVan, D.A., Synthetic protocells interact with viral nanomachinery and inactivate pathogenic human virus. PLoS One, 6, 2011, e16874.
244. [244] Wang, D., Huang, J., Wang, X., Yu, Y., Zhang, H., Chen, Y., Liu, J., Sun, Z., Zou, H., Sun, D., Zhou, G., Zhang, G., Lu, Y., Zhong, Y., The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials 34 (2013), 7662–7673.
245. [245] Zhang, X., Li, F., Guo, S., Chen, X., Wang, X., Li, J., Gan, Y., Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. Biomaterials 35 (2014), 3650–3665.
246. [246] Roggers, R.A., Lin, V.S.-Y., Trewyn, B.G., Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and hela and normal mouse liver biocompatibility and cellular internalization. Mol. Pharm. 9 (2012), 2770–2777.
247. [247] Hu, C.-M.J., Zhang, L., Aryal, S., Cheung, C., Fang, R.H., Zhang, L., Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. 108 (2011), 10980–10985.
248. [248] Kumar, R., Roy, I., Ohulchanskky, T.Y., Vathy, L.A., Bergey, E.J., Sajjad, M., In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano 4 (2010), 699–708.
249. [249] Liu, T., Li, L., Teng, X., Huang, X., Liu, H., Chen, D., Ren, J., He, J., Tang, F., Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. Biomaterials 32 (2011), 1657–1668.
250. [250] Chen, Y., Wang, X., Liu, T., Zhang, D.S., Wang, Y., Gu, H., Di, W., Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy. Int. J. Nanomedicine 10 (2015), 2579–2594.
251. [251] Kim, J., Kim, H.S., Lee, N., Kim, T., Kim, H., Yu, T., Song, I.C., Moon, W.K., Hyeon, T., Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed. 47 (2008), 8438–8443.
252. [252] Wu, S.-H., Lin, Y.-S., Hung, Y., Chou, Y.-H., Hsu, Y.-H., Chang, C., Mou, C.-Y., Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies. Chembiochem 9 (2008), 53–57.
253. [253] Nielsen, U.B., Kirpotin, D.B., Pickering, E.M., Drummond, D.C., Marks, J.D., A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol., 7, 2006, 24.
254. [254] Mérian, J., Gravier, J., Navarro, F., Texier, I., Fluorescent nanoprobes dedicated to in vivo imaging: from preclinical validations to clinical translation. Molecules 17 (2012), 5564–5591.
255. [255] Benezra, M., Penate-Medina, O., Zanzonico, P.B., Schaer, D., Ow, H., Burns, A., DeStanchina, E., Longo, V., Herz, E., Iyer, S., Wolchok, J., Larson, S.M., Wiesner, U., Bradbury, M.S., Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Investig. 121 (2011), 2768–2780.
256. [256] Bradbury, M.S., Phillips, E., Montero, P.H., Cheal, S.M., Stambuk, H., Durack, J.C., Sofocleous, C.T., Meester, R.J., Wiesner, U., Patel, S., Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr. Biol. 5 (2013), 74–86.
257. [257] Taratula, O., Garbuzenko, O.B., Chen, A.M., Minko, T., Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 19 (2011), 900–914.
258. [258] Meng, H., Mai, W.X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J.I., Nel, A.E., Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7 (2013), 994–1005.
259. [259] Nehoff, H., Parayath, N.N., Domanovitch, L., Taurin, S., Greish, K., Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomedicine 9 (2014), 2539–2555.
260. [260] Prabhakar, U., Maeda, H., Jain, R.K., Sevick-Muraca, E.M., Zamboni, W., Farokhzad, O.C., Barry, S.T., Gabizon, A., Grodzinski, P., Blakey, D.C., Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73 (2013), 2412–2417.
261. [261] Gao, F., Botella, P., Corma, A., Blesa, J., Dong, L., Monodispersed mesoporous silica nanoparticles with very large pores for enhanced adsorption and release of DNA. J. Phys. Chem. B 113 (2009), 1796–1804.
262. [262] Yang, H., Zheng, K., Zhang, Z., Shi, W., Jing, S., Wanga, L., Zheng, W., Zhao, D., Xu, J., Zhang, P., Adsorption and protection of plasmid DNA on mesoporous silica nanoparticles modified with various amounts of organosilane. J. Colloid Interface Sci. 369 (2012), 317–322.
263. [263] Bhattarai, S.R., Muthuswamy, E., Wani, A., Brichacek, M., Castañeda, A.L., Brock, S.L., Oupicky, D., Enhanced gene and siRNA delivery by polycation-modified mesoporous silica nanoparticles loaded with chloroquine. Pharm. Res. 27 (2010), 2556–2568.
264. [264] Chen, W., Tsai, P.-H., Hung, Y., Chiou, S.-H., Mou, C.-Y., Nonviral cell labeling and differentiation agent for induced pluripotent stem cells based on mesoporous silica nanoparticles. ACS Nano 7 (2013), 8423–8440.
265. [265] Du, X., Shi, B., Tang, Y., Dai, S., Qiao, S.Z., Label-free dendrimer-like silica nanohybrids for traceable and controlled gene delivery. Biomaterials 35 (2014), 5580–5590.
266. [266] Kim, M.H., Na, H.K., Kim, Y.K., Ryoo, S.R., Cho, H.S., Lee, K.E., Jeon, H., Ryoo, R., Min, D.H., Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery. ACS Nano 5 (2011), 3568–3576.
267. [267] Radu, D.R., Lai, C.Y., Jeftinija, K., Rowe, E.W., Jeftinija, S., Lin, V.S., A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J. Am. Chem. Soc. 126 (2004), 13216–13217.
268. [268] Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J.I., Nel, A.E., Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano 3 (2009), 3273–3286.
269. [269] Wang, Z., Liu, G., Zheng, H., Chen, X., Rigid nanoparticle based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol. Adv. 32 (2014), 831–843.
270. [270] Guo, W., Tian, H., Dong, X., Bai, J., Yang, X., Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells. Int. J. Clin. Exp. Pathol. 8 (2015), 7762–7773.
271. [271] Salameh, A., Lee, A.K., Cardó-Vila, M., Nunes, D.N., Efstathiou, E., Staquicini, F.I., Dobroff, A.S., Marchiò, S., Navone, N.M., Hosoya, H., Lauer, R.C., Wen, S.J., Salmeron, C.C., Hoang, A., Newsham, I., Lima, L.A., Carraro, D.M., Oliviero, S., Kolonin, M.G., Sidman, R.L., Do, K.A., Troncoso, P., Logothetis, C.J., Brentani, R.R., Calin, G.A., Cavenee, W.K., Dias-Neto, E., Pasqualini, R., Arap, W., PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 8403–8408.
272. [272] Miele, E., Spinelli, G.P., Miele, E., Di Fabrizio, E., Ferretti, E., Tomao, S., Gulino, A., Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int. J. Nanomedicine 7 (2012), 3637–3657.
273. [273] Lee, S.J., Yook, S., Yhee, J.Y., Yoon, H.Y., Kim, M.G., Ku, S.H., Kim, S.H., Park, J.H., Jeong, J.H., Kwon, I.C., Lee, S., Lee, H., Kim, K., Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo. J. Control. Release, 2015.
274. [274] Ku, S.H., Kim, K., Choi, K., Kim, S.H., Kwon, I.C., Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy. Adv. Healthcare Mater. 3 (2014), 1182–1193.
275. [275] Chen, A.M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., He, H., Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5 (2009), 2673–2677.
276. [276] Hom, C., Lu, J., Liong, M., Luo, H., Li, Z., Zink, J.I., Tamanoi, F., Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 6 (2010), 1185–1190.
277. [277] Ma, X., Zhao, Y., Ng, K.W., Zhao, Y., Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chem. Eur. J. 19 (2013), 15593–15603.
278. [278] Li, X., Xie, Q.R., Zhanga, J., Xia, W., Gu, H., The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 32 (2011), 9546–9556.
279. [279] Finlay, J., Roberts, C.M., Dong, J., Zink, J.I., Tamanoi, F., Glackin, C.A., Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomed. Nanotechnol. Biol. Med. 11 (2015), 1657–1666.
280. [280] Li, X., Chen, Y., Wang, M., Ma, Y., Xia, W., Gu, H., A mesoporous silica nanoparticle e PEI e fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 34 (2013), 1391–1401.
281. [281] Morry, J., Ngamcherdtrakul, W., Gu, S., Goodyear, S.M., Castro, D.J., Reda, M.M., Sangvanich, T., Yantasee, W., Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials 66 (2015), 41–52.
282. [282] Ngamcherdtrakul, W., Morry, J., Gu, S., Castro, D.J., Goodyear, S.M., Sangvanich, T., Reda, M.M., Lee, R., Mihelic, S.A., Beckman, B.L., Hu, Z., Gray, J.W., Yantasee, W., Cationic polymer modified mesoporous silica nanoparticles for targeted SiRNA delivery to HER2 + breast cancer. Adv. Funct. Mater. 25 (2015), 2646–2659.
283. [283] Shen, J., Kim, H.-C., Su, H., Wang, F., Wolfram, J., Kiriu, D., Mai, J., Mu, C., Ji, L.-N., Mao, Z.-W., Shen, H., Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics 4 (2014), 487–497.
284. [284] El-Sayed, A., Futaki, S., Harashima, H., Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 11 (2009), 13–22.
285. [285] Hou, K.K., Pan, H., Schlesinger, P.H., Wickline, S.A., A role for peptides in overcoming endosomal entrapment in siRNA delivery — a focus on melittin. Biotechnol. Adv. 33 (2015), 931–940.
286. [286] Hattori, Y., Nakamura, A., Arai, S., Kawano, K., Maitani, Y., Yonemochi, E., siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. J. Liposome Res. 38 (2015), 30–38.
287. [287] Mudhakir, D., Akita, H., Tan, E., Harashima, H., A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway. J. Control. Release 125 (2008), 164–173.
288. [288] Nakamura, Y., Kogure, K., Futaki, S., Harashima, H., Octaarginine-modified multifunctional envelope-type nano device for siRNA. J. Control. Release 119 (2007), 360–367.
289. [289] Taetz, S., Bochot, A., Surace, C., Arpicco, S., Renoir, J.M., Schaefer, U.F., Marsaud, V., Kerdine-Roemer, S., Lehr, C.M., Fattal, E., Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Oligonucleotides 19 (2009), 103–116.
290. [290] Hyndman, L., Lemoine, J.L., Huang, L., Porteous, D.J., Boyd, A.C., Nan, X., HIV-1 Tat protein transduction domain peptide facilitates gene transfer in combination with cationic liposomes. J. Control. Release 99 (2004), 435–444.
291. [291] Kale, A.A., Torchilin, V.P., Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes. J. Drug Target. 15 (2007), 538–545.
292. [292] Yu, D.D., Wang, C.T., Shi, H.S., Li, Z.Y., Pan, L., Yuan, Q.Z., Leng, F., Wen, Y., Chen, X., Wei, Y.Q., Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant. J. Exp. Clin. Cancer Res., 29, 2010, 46.
293. [293] Keefe, A.D., Pia, S., Ellington, A., Aptamers as therapeutics. Nat. Rev. Drug Discov. 9 (2010), 537–550.
294. [294] Sundaram, P., Kurniawan, H., Byrne, M., Wower, J., Therapuetic RNA aptamers in clinical trials. Eur. J. Pharm. Sci. 48 (2013), 259–271.
295. [295] Lee, S.K., Park, M.W., Yang, E.G., Yu, J., Jeong, S., An RNA aptamer that binds to the b-catenin interaction domain of TCF-1 protein. Biochem. Biophys. Res. Commun. 327 (2005), 294–299.
296. [296] Lee, H.K., Choi, Y.S., Park, Y.A., Jeong, S., Modulation of oncogenic transcription and alternative splicing by B-catenin and an RNA aptamer in colon cancer cells. Cancer Res. 66 (2006), 10560–10566.
297. [297] Bardeesy, N., Pelletier, J., Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. Nucleic Acids Res. 26 (1998), 1784–1792.
298. [298] An, Y., Wu, J., Yang, B., Zhu, Z., Gao, M., Yu, C., Yang, C.J., Selection and application of DNA aptamer against oncogene amplified in breast cancer 1. J. Mol. Evol. 81 (2015), 179–185.
299. [299] Guo, W.M., Kong, K.W., Brown, C.J., Quah, S.T., Yeo, H.L., Hoon, S., Seow, Y., Identification and characterization of an eIF4e DNA aptamer that inhibits proliferation with high throughput sequencing molecular therapy. Nucleic Acids, 3, 2014, e217.
300. [300] Slupianek, A., Dasgupta, Y., Ren, S., Gurdek, E., Donlin, M., Nieborowska-Skorska, M., Fleury, F., Skorski, T., Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood 118 (2011), 1062–1068.
301. [301] Rérole, A., Gobbo, J., De Thonel, A., Schmitt, E., de Barros, J.P.P., Hammann, A., Lanneau, D., Fourmaux, E., Deminov, O., Micheau, O., Lagrost, L., Colas, P., Kroemer, G., Garrido, C., Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 71 (2011), 484–495.
302. [302] Gibert, B., Simon, S., Dimitrova, V., Diaz-Latoud, C., Arrigo, A.-P., Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function. Philos. Trans. R. Soc. B, 368, 2013, 20120075.
303. [303] Jølck, R., Feldborg, L., Andersen, S., Moghimi, S.M., Andresen, T., Engineering liposomes and nanoparticles for biological targeting. Nyanhongo, G.S., Steiner, W., Gübitz, G., (eds.) Biofunctionalization of Polymers and Their Applications, 2011, Springer, Berlin Heidelberg, 251–280.
304. [304] Nobs, L., Buchegger, F., Gurny, R., Allémann, E., Current methods for attaching targeting ligands to liposomes and nanoparticles. J. Pharm. Sci. 93 (2004), 1980–1992.
305. [305] Sperling, R.A., Parak, W.J., Surface Modification, Functionalization and Bioconjugation of Colloidal Inorganic Nanoparticles. 2010.
306. [306] Santra, S., Yang, H., Dutta, D., Stanley, J.T., Holloway, P.H., Tan, W., Moudgil, B.M., Mericle, R.A., TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem. Commun., 2004, 2810–2811.
307. [307] Martin, F.J., Hubbell, W.L., Papahadjopoulos, D., Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab’ fragments via disulfide bonds. Biochemistry 20 (1981), 4229–4238.
308. [308] Shaik, M.S., Kanikkannan, N., Singh, M., Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin. J. Control. Release 76 (2001), 285–295.
309. [309] Kirpotin, D., Park, J.W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C.C., Papahadjopoulos, D., Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36 (1997), 66–75.
310. [310] Park, J.W., Hong, K., Carter, P., Asgari, H., Guo, L.Y., Keller, G.A., Wirth, C., Shalaby, R., Kotts, C., Wood, W.I., Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. 92 (1995), 1327–1331.
311. [311] Park, J.W., Hong, K., Kirpotin, D.B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U.B., Marks, J.D., Moore, D., Papahadjopoulos, D., Benz, C.C., Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8 (2002), 1172–1181.
312. [312] Marqués-Gallego, P., de Kroon, A.I.P.M., Ligation strategies for targeting liposomal nanocarriers. BioMed Rese. Int., 2014, 2014, 129458.
313. [313] Kolb, H.C., Finn, M.G., Sharpless, K.B., Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40 (2001), 2004–2021.
314. [314] Baskin, J.M., Prescher, J.A., Laughlin, S.T., Agard, N.J., Chang, P.V., Miller, I.A., Lo, A., Codelli, J.A., Bertozzi, C.R., Copper-free click chemistry for dynamic in vivo imaging. Proc. Natl. Acad. Sci. 104 (2007), 16793–16797.
315. [315] Blackman, M.L., Royzen, M., Fox, J.M., Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels–Alder reactivity. J. Am. Chem. Soc. 130 (2008), 13518–13519.
316. [316] Schmitt, J., Hess, H., Stunnenberg, H., Affinity purification of histidine-tagged proteins. Mol. Biol. Rep. 18 (1993), 223–230.
317. [317] Janknecht, R., de Martynoff, G., Lou, J., Hipskind, R.A., Nordheim, A., Stunnenberg, H.G., Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 8972–8976.
318. [318] Hainfeld, J.F., Liu, W., Halsey, C.M.R., Freimuth, P., Powell, R.D., Ni–NTA–gold clusters target his-tagged proteins. J. Struct. Biol. 127 (1999), 185–198.
319. [319] Parry, D.A., Fraser, R.D., Squire, J.M., Fifty years of coiled-coils and alpha-helical bundles: a close relationship between sequence and structure. J. Struct. Biol. 163 (2008), 258–269.
320. [320] Litowski, J.R., Hodges, R.S., Designing heterodimeric two-stranded alpha-helical coiled-coils. Effects of hydrophobicity and alpha-helical propensity on protein folding, stability, and specificity. J. Biol. Chem. 277 (2002), 37272–37279.
321. [321] Mortier, J., Nyakatura, E.K., Reimann, O., Huhmann, S., Daldrop, J.O., Baldauf, C., Wolber, G., Miettinen, M.S., Koksch, B., Coiled-coils in phage display screening: insight into exceptional selectivity provided by molecular dynamics. J. Chem. Inf. Model. 55 (2015), 495–500.
322. [322] Ayriss, J., Woods, T., Bradbury, A., Pavlik, P., High-throughput screening of single-chain antibodies using multiplexed flow cytometry. J. Proteome Res. 6 (2007), 1072–1082.
323. [323] Velappan, N., Fisher, H.E., Pesavento, E., Chasteen, L., D'Angelo, S., Kiss, C., Longmire, M., Pavlik, P., Bradbury, A.R., A comprehensive analysis of filamentous phage display vectors for cytoplasmic proteins: an analysis with different fluorescent proteins. Nucleic Acids Res., 38, 2010, e22.
324. [324] Hiller, Y., Gershoni, J.M., Bayer, E.A., Wilchek, M., Biotin binding to avidin. Oligosaccharide side chain not required for ligand association., 1987.
325. [325] Green, N.M., Avidin and streptavidin. Methods Enzymol. 184 (1990), 51–67.
326. [326] Kawato, T., Mizohata, E., Shimizu, Y., Meshizuka, T., Yamamoto, T., Takasu, N., Matsuoka, M., Matsumura, H., Kodama, T., Kanai, M., Doi, H., Inoue, T., Sugiyama, A., Structure-based design of a streptavidin mutant specific for an artificial biotin analogue. J. Biochem. 157 (2015), 467–475.
327. [327] Weir, C., Hudson, A.L., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S.J., Pavlakis, N., Davey, R., Howell, V.M., Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunol. Res. 2 (2014), 469–479.
328. [328] Yumura, K., Ui, M., Doi, H., Hamakubo, T., Kodama, T., Tsumoto, K., Sugiyama, A., Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin. Protein Sci. 22 (2013), 213–221.
329. [329] Torchilin, V.P., Goldmacher, V.S., Smirnov, V.N., Comparative studies on covalent and noncovalent immobilization of protein molecules on the surface of liposomes. Biochem. Biophys. Res. Commun. 85 (1978), 983–990.
330. [330] Torchilin, V.P., Khaw, B.A., Smirnov, V.N., Haber, E., Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 89 (1979), 1114–1119.
331. [331] Mitra, M., Mandal, A.K., Chatterjee, T.K., Das, N., Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J. Drug Target. 13 (2005), 285–293.
332. [332] Bäumert, H.G., Fasold, H., [32] Cross-linking techniques. Methods in Enzymology, 1989, Academic Press, 584–609.
333. [333] Kim, E., Wriggers, W., Phillips, M., Kokabi, K., Rubenstein, P.A., Reisler, E., Cross-linking constraints on F-actin structure1. J. Mol. Biol. 299 (2000), 421–429.
334. [334] Peng, H., Chen, W., Cheng, Y., Hakuna, L., Strongin, R., Wang, B., Thiol reactive probes and chemosensors. Sensors, 12, 2012, 15907.
335. [335] Yu, M.K., Park, J., Jon, S., Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2 (2012), 3–44.
336. [336] Werengowska-Ciecwierz, K., Wisniewski, M., Terzyk, A.P., Furmaniak, S., The chemistry of bioconjugation in nanoparticles-based drug delivery system. Adv. Condens. Matter Phys., 2015, 2015.
337. [337] Conde, J., Dias, J.T., Grazú, V., Moros, M., Baptista, P.V., De La Fuente, J.M., Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front. Chem., 2, 2014.
338. [338] Conde, J., Ambrosone, A., Sanz, V., Hernandez, Y., Marchesano, V., Tian, F., Child, H., Berry, C.C., Ibarra, M.R., Baptista, P.V., Tortiglione, C., de la Fuente, J.M., Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano 6 (2012), 8316–8324.
339. [339] Koo, H., Lee, S., Na, J.H., Kim, S.H., Hahn, S.K., Choi, K., Kwon, I.C., Jeong, S.Y., Kim, K., Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles. Angew. Chem. Int. Ed. 51 (2012), 11836–11840.
340. [340] Cardó-Vila, M., Arap, W., Pasqualini, R., Alpha v beta 5 integrin-dependent programmed cell death triggered by a peptide mimic of annexin V. Mol. Cell 11 (2003), 1151–1162.
341. [341] Burg, M.A., Pasqualini, R., Arap, W., Ruoslahti, E., Stallcup, W.B., NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59 (1999), 2869–2874.
342. [342] Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila, P., Kantor, C., Gahmberg, C.G., Salo, T., Konttinen, Y.T., Sorsa, T., Ruoslahti, E., Pasqualini, R., Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17 (1999), 768–774.
343. [343] Giordano, R.J., Anobom, C.D., Cardó-Vila, M., Kalil, J., Valente, A.P., Pasqualini, R., Almeida, F.C., Arap, W., Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. Chem. Biol. 12 (2005), 1075–1083.
344. [344] Jaalouk, D.E., Ozawa, M.G., Sun, J., Lahdenranta, J., Schlingemann, R.O., Pasqualini, R., Arap, W., The original Pathologische Anatomie Leiden-endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1. Cancer Res. 67 (2007), 9623–9629.
345. [345] Karjalainen, K., Jaalouk, D.E., Bueso-Ramos, C.E., Zurita, A.J., Kuniyasu, A., Eckhardt, B.L., Marini, F.C., Lichtiger, B., O'Brien, S., Kantarjian, H.M., Cortes, J.E., Koivunen, E., Arap, W., Pasqualini, R., Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117 (2011), 920–927.
346. [346] Daquinag, A.C., Tseng, C., Zhang, Y., Amaya-Manzanares, F., Florez, F., Dadbin, A., Zhang, T., Kolonin, M.G., Targeted proapoptotic peptides depleting adipose stromal cells inhibit tumor growth. Mol. Ther., 2015.
347. [347] Hossen, M.N., Kajimoto, K., Akita, H., Hyodo, M., Ishitsuka, T., Harashima, H., Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. J. Control. Release 147 (2010), 261–268.
348. [348] Vidal, C.I., Mintz, P.J., Lu, K., Ellis, L.M., Manenti, L., Giavazzi, R., Gershenson, D.M., Broaddus, R., Liu, J., Arap, W., Pasqualini, R., An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 23 (2004), 8859–8867.
349. [349] Oh, Y., Mohiuddin, I., Sun, Y., Putnam, J.B. Jr., Hong, W.K., Arap, W., Pasqualini, R., Phenotypic diversity of the lung vasculature in experimental models of metastases. Chest 128 (2005), 596S–600S.
350. [350] Bover, L.C., Cardó-Vila, M., Kuniyasu, A., Sun, J., Rangel, R., Takeya, M., Aggarwal, B.B., Arap, W., Pasqualini, R., A previously unrecognized protein–protein interaction between TWEAK and CD163: potential biological implications. J. Immunol. 178 (2007), 8183–8194.
351. [351] Staquicini, F.I., Tandle, A., Libutti, S.K., Sun, J., Zigler, M., Bar-Eli, M., Aliperti, F., Perez, E.C., Gershenwald, J.E., Mariano, M., Pasqualini, R., Arap, W., Lopes, J.D., A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 68 (2008), 8419–8428.
352. [352] Moeller, B.J., Sidman, R.L., Pasqualini, R., Arap, W., Discovery of DNA repair inhibitors by combinatorial library profiling. Cancer Res. 71 (2011), 1816–1824.
353. [353] Bartolini, A., Di Paolo, D., Noghero, A., Murgia, D., Sementa, A.R., Cilli, M., Pasqualini, R., Arap, W., Bussolino, F., Ponzoni, M., Pastorino, F., Marchiò, S., The neuronal pentraxin-2 pathway is an unrecognized target in human neuroblastoma, which also offers prognostic value in patients. Cancer Res. 75 (2015), 4265–4271.
354. [354] Rangel, R., Guzman-Rojas, L., le Roux, L.G., Staquicini, F.I., Hosoya, H., Barbu, E.M., Ozawa, M.G., Nie, J., Jr, K.D., Langley, R.R., Sage, E.H., Koivunen, E., Gelovani, J.G., Lobb, R.R., Sidman, R.L., Pasqualini, R., Arap, W., Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells. Nat. Commun., 3, 2012, 788.
355. [355] Marchiò, S., Soster, M., Cardaci, S., Muratore, A., Bartolini, A., Barone, V., Ribero, D., Monti, M., Bovino, P., Sun, J., Giavazzi, R., Asioli, S., Cassoni, P., Capussotti, L., Pucci, P., Bugatti, A., Rusnati, M., Pasqualini, R., Arap, W., Bussolino, F., A complex of alpha6 integrin and E-cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietin-like 6. EMBO Mol. Med. 4 (2012), 1156–1175.
356. [356] Lee, J., Chatterjee, D.K., Lee, M.H., Krishnana, S., Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett. 347 (2014), 46–53.
357. [357] Li, R., Wu, R., Zhao, L., Qin, H., Wu, J., Zhang, J., Bao, R., Zou, H., In vivo detection of magnetic labeled oxidized multi-walled carbon nanotubes by magnetic resonance imaging. Nanotechnology, 25, 2014, 495102.